Melanoma Clinical Trials in Baltimore

Showing 281-300 of 320 trials

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

NCT00003802

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have metastatic skin or eye melanoma.

Intraocular MelanomaMelanoma (Skin)

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsStarted Feb 1999

Baltimore, Maryland, United States

COMPLETEDPhase 3< 1 mile

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205

This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)

Melanoma

AstraZeneca655 participantsStarted Mar 2006

Huntsville, Alabama, United States • Mobile, Alabama, United States • Scottsdale, Arizona, United States +140 more locations

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Melanoma Trials in Other Cities

Study of CP-675,206 in Refractory Melanoma

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Isotretinoin in Preventing Skin Cancer

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Other Conditions in Baltimore